"We observed that PrCa cells are resistant to clinically relevant doses of MET. Combined MET + SAL treatment provides synergistic anti-proliferative activity at clinically relevant doses and enhances the anti-proliferative effects of RT. This was associated with suppression of oxygen consumption rate (OCR), activation of AMPK, suppression of acetyl-CoA carboxylase (ACC)-DNL and mTOR-p70s6k/4EBP1 and HIF1α pathways. MET + SAL reduced tumor growth in non-irradiated tumors and enhanced the effects of RT."
Taking aspirin has potential benefits (my primary care doctor has me on 2k IU of vitamin D each day and 81 mg of aspirin each night). The more "conventional" benefits of aspirin are blood thinning and therefore reduced stroke risk. But the downside is risk of bleeding (hard to reduce clotting activity but keep clotting activity Some drugs or supplements increase these risks. Depending on the supplement or drug they might also increase the potential benefits.
Risk mitigation and walking in the middle of the road is why he picked the 81 mg (baby aspirin).
For RT maybe a higher dose could be taken temporarily? As cigafred points out, this is a petri dish study. Maybe something good will come of it, maybe not. The NIH has done some RCTs using metformin with RT and with aspirin with RT but I don't see any combo studies.
Good article though and one that I will keep in my "future/radiation" bookmarks.
Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis
I came across this reference to a paper below. I, myself have taken aminosalisylicate suppositories (Pentasa 1g) for proctitus. It certainly worked for the proctitus.
Aminosalicylates Cut PCa Risk in Men with IBD
Jody A. Charnow
prostate cancer-0516
Researchers found an adjusted 68% decreased risk of prostate cancer in men with IBD who used aminosalicylate.
Aminosalicylate use by men with inflammatory bowel disease (IBD) is associated with a decreased risk of prostate cancer (PCa), investigators reported online in the Journal of Gastroenterology.
J. Clair Wilson, PhD, of the University of Basel in Switzerland, and colleagues identified 1,077 cancers among 19,647 patients with a first-time diagnosis of IBD and a randomly matched group of an equal number of patients without IBD. The researchers observed no association between IBD and overall cancer risk, but aminosalicylate use by IBD patients was associated with adjusted 68% decreased risk of PCa and 28% decreased risk of all cancers.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Some drugs or supplements increase these risks. Depending on the supplement or drug they might also increase the potential benefits. 
Does IP6 Have New Support from A Mayo Physician Report?
New prostate cancer treatment concept
